Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

Name: Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
License: Public Domain

Fujian Cancer Hospital

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

immunotherapy

metastatic colorectal cancer with left-sided primary tumor, immunotherapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 230417
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.